First-Line Camrelizumab Plus Rivoceranib Maintains Survival ... - OncLive
Rivoceranib plus camrelizumab showed improved survival over sorafenib in advanced HCC, with median OS of 23.8 vs 15.2 months and PFS of 5.6 vs 3.7 months. The combination's safety profile supports its use as a first-line treatment, despite FDA concerns over manufacturing site deficiencies.
Related Clinical Trials
Reference News
First-Line Camrelizumab Plus Rivoceranib Maintains Survival ... - OncLive
Rivoceranib plus camrelizumab showed improved survival over sorafenib in advanced HCC, with median OS of 23.8 vs 15.2 months and PFS of 5.6 vs 3.7 months. The combination's safety profile supports its use as a first-line treatment, despite FDA concerns over manufacturing site deficiencies.